Newron Pharmaceuticals S.p.A. | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Headlines Articles Press releases Newron Pharmaceuticals S.p.A.

Home
Companies
Newron Pharmaceuticals S.p.A.

BRIEF

published on 10/02/2025 at 07:05, 2 months 2 days ago

Newron Pharmaceuticals Highlights Evenamide at ECNP Congress 2025

Clinical Trial Schizophrenia Newron Pharmaceuticals Evenamide ECNP Congress
PRESS RELEASE

published on 10/02/2025 at 07:00, 2 months 2 days ago

Newron to present new analyses from and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 38th ECNP Congress 2025
Newron Pharmaceuticals to present new analyses and updates on evenamide as treatment for schizophrenia at the 38th ECNP Congress 2025

Clinical Program Schizophrenia Newron Pharmaceuticals Evenamide ECNP Congress
BRIEF

published on 09/16/2025 at 07:05, 2 months 18 days ago

Newron Pharmaceuticals Unveils H1 2025 Results and Strategic Advancements

Strategic Partnerships Clinical Trials Newron Pharmaceuticals Evenamide Schizophrenia Treatment
PRESS RELEASE

published on 09/16/2025 at 07:00, 2 months 18 days ago

Newron presents H1 2025 results and provides business update
Newron Pharmaceuticals S.p.A. presents H1 2025 financial results and business update, focusing on evenamide therapy for treatment-resistant schizophrenia patients and strategic partnerships

Business Update Newron Pharmaceuticals Schizophrenia Treatment H1 2025 Results Evenamide Therapy
BRIEF

published on 09/05/2025 at 07:05, 2 months 29 days ago

Newron Pharmaceuticals to Reveal Evenamide Insights at 2025 WCBP

Newron Pharmaceuticals Evenamide Schizophrenia Treatment Clinical Trial Updates Glutamate Modulation
PRESS RELEASE

published on 09/05/2025 at 07:00, 2 months 29 days ago

Newron to present data and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP)
Newron Pharmaceuticals to present data on evenamide as add-on treatment for schizophrenia at 2025 WCBP. Focus on efficacy, safety, and mechanism of action. Landmark studies showcased

Clinical Program Schizophrenia Newron Pharmaceuticals Evenamide WCBP
BRIEF

published on 08/12/2025 at 07:05, 3 months 23 days ago

Newron Initiates Phase III ENIGMA-TRS Study for Treatment-Resistant Schizophrenia

Newron Pharmaceuticals Evenamide Schizophrenia Treatment Phase III Study TRS Therapy
PRESS RELEASE

published on 08/12/2025 at 07:00, 3 months 23 days ago

Newron begins enrollment in pivotal Phase III ENIGMA-TRS program with evenamide as add-on therapy in patients with treatment-resistant schizophrenia (TRS)
Newron Pharmaceuticals initiates Phase III ENIGMA-TRS program with evenamide as add-on therapy for treatment-resistant schizophrenia patients, targeting TRS population

Newron Pharmaceuticals Evenamide Phase III Treatment-resistant Schizophrenia ENIGMA-TRS Program
BRIEF

published on 08/11/2025 at 07:05, 3 months 24 days ago

Newron Pharmaceuticals' Evenamide Shows Promise in Schizophrenia Treatment

Newron Pharmaceuticals Schizophrenia Treatment Evenamide Research Glutamate Modulation Neuropsychopharmacology Study
PRESS RELEASE

published on 08/11/2025 at 07:00, 3 months 24 days ago

Newron notes the publication of new preclinical research suggesting evenamide ameliorates schizophrenia-related dysfunction
Newron Pharmaceuticals notes new preclinical research indicating evenamide may improve schizophrenia-related dysfunction by targeting hippocampal pathology. Study shows potential for novel therapeutic strategy

Schizophrenia Newron Pharmaceuticals Evenamide Preclinical Research Hippocampus

1 2 ... 6

Accesswire

Published on 12/05/2025 at 02:35, 2 hours 52 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 2 hours 57 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 4 hours 27 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 6 hours 22 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 6 hours 27 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 1 hour 57 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 5 hours 36 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 2 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 12 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 16 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 11 hours 27 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 11 hours 42 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 11 hours 43 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 22 hours 26 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 11 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE